

June 6, 2024

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Office of Life Sciences

**Re: Prelude Therapeutics Incorporated
Registration Statement on Form S-3
Filed May 30, 2024
File No. 333-279829**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Prelude Therapeutics Incorporated (the "Company") hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on June 10, 2024, or as soon as practicable thereafter.

PRELUDE THERAPEUTICS INCORPORATED

By: /s/ Bryant D. Lim

Name: Bryant D. Lim

Title: Chief Legal Officer, Secretary & Interim Chief
Financial Officer

cc: Richard B. Aldridge, *Morgan, Lewis & Bockius LLP*
Bryan S. Keighery, *Morgan, Lewis & Bockius LLP*